The office visit rarely pays the bills. The ancillaries do.
Independent urology earns its margin in ancillary and procedure lines: in-office labs and pathology, imaging, lithotripsy, in-office BPH procedures, and advanced prostate cancer care. Those lines carry equipment cost, drug cost, and payer policy exposure that a blended revenue report will not show. The monthly briefing reads each on its own contribution alongside the standard revenue-cycle picture.
Where the specialty stands
Urology is a procedure- and ancillary-heavy specialty where in-office labs, imaging, lithotripsy, and increasingly radiation/UroLift drive most of the margin. Independent groups are building large single-specialty platforms (LUGPA-style) to retain ancillaries that hospitals and payers keep pressuring.
- Large urology group platforms (LUGPA model) continue consolidating to preserve in-office services such as pathology, imaging, and radiation oncology.
- Advanced prostate cancer drugs and in-office dispensing are a growing but compliance-heavy revenue line.
- Site-of-service pressure and prior auth on advanced imaging (mpMRI, PSMA PET) shape access and throughput.
- UroLift, Rezum, and other in-office BPH procedures are shifting cases out of the OR and into the clinic.
- Workforce: a well-documented urologist shortage makes APP leverage and retention a core operational lever.
What the briefing reads for a urology practice
Pathology, imaging, lithotripsy, and in-office procedures read separately after direct cost, staffing, and equipment. One weak line can absorb the margin the others produce.
Volume moving between office, ASC, and hospital settings, and what each shift does to collections and cost.
Drug acquisition cost, payer payment, and payment timing for injectable therapies, tracked as working capital rather than as ordinary revenue.
Approval turnaround and denial reasons for imaging, drugs, and procedures, grouped by payer so the pattern points at policy rather than at coding.
Third next available, new patient share, and how advanced practice providers are used against physician capacity.
Illustrative reference ranges
Read the methodologyThese internally authored, industry-informed estimates provide specialty context. They are not live peer data, licensed survey medians, targets, or promises.
| Indicator | Lower reference | Central reference | Upper reference |
|---|---|---|---|
| Revenue per provider (monthly) | $78k | $98k | $120k |
| Days in A/R | 31 days | 39 days | 47 days |
| Average reimbursement rate | 63% | 71% | 79% |
| Contractual adjustment rate | 26% | 32% | 38% |
| Operating expense ratio | 58% | 64% | 70% |
| Scheduling efficiency | 72% | 80% | 88% |
| Net collection rate | 93.4% | 96% | 97.8% |
| Commercial payer mix | 48% | 60% | 72% |
| Third next available appointment | 7 days | 12 days | 18 days |
| No-show rate | 5% | 7.8% | 10.5% |
| Staff per provider | 2.7 | 3.3 | 3.9 |
| Provider turnover | 4% | 7% | 11% |
| Training investment (% of payroll) | 1.1% | 1.9% | 2.7% |
| Cost per visit | $190 | $230 | $280 |
| Patient satisfaction | 4.2 / 5 | 4.5 / 5 | 4.7 / 5 |
| Quality compliance rate | 87% | 92% | 96% |
Questions this briefing is built to answer
- Which ancillary lines are actually profitable once staffing and equipment are counted?
- Is drug payment keeping up with acquisition cost and timing?
- What would moving specific procedures in-office do to margin?
- Where are authorization delays costing us schedule capacity?
- Are advanced practice providers improving access or absorbing it?
- Is equipment we own producing enough volume to justify its cost?
What we read to stay current
See what this looks like for your practice
Send aggregate practice data for a recent period and we will show you the executive brief format: what changed, why it may matter, likely drivers, and what to watch.
AileronMD analyzes business, financial, and operational data only. Do not submit patient records or protected health information. AileronMD does not provide clinical or medical advice, and does not guarantee financial results. Guidance is advisory; practice leadership makes the decisions.